Yarom, Noam
Van Poznak, Catherine H.
Epstein, Joel B.
Ottaviani, Giulia
Matsuda, Yuhei
Migliorati, Cesar
Elad, Sharon
Funding for this research was provided by:
Tel Aviv University
Article History
Received: 5 June 2024
Accepted: 24 June 2024
First Online: 25 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: N. Yarom, G. Ottaviani, Y. Matsuda, and S. Elad reported no relevant financial or non-financial interests to disclose. C. H. Van Poznak received funding from Bayer for a clinical trial unrelated to the subject matter. J. B. Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, and Nielsen Inc. C. Migliorati is an adjudicator for Amgen Inc. J. B. Epstein is also the Associate Editor-in-Chief for <i>Supportive Care in Cancer</i>.
: The MASCC/ISOO OCSG Statements have been developed to facilitate expert opinion-based management of oral complications of cancer and cancer therapy, where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.